Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?

J Nucl Med. 2026 May 1;67(5):667-671. doi: 10.2967/jnumed.125.271153.

Philipp E Hartrampf^{1

2

3}, Rudolf A Werner⁴, Takahiro Higuchi^{1

2

3

5

6}, Margret Schottelius^{7

8}, Andreas K Buck^{9

2

3

5

6}

¹ Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
² National Cancer Centre, NCT WERA, University Hospital Würzburg, Würzburg, Germany.
³ Bavarian Centre for Cancer Research, Erlangen, Germany.
⁴ Department of Nuclear Medicine, Ludwig Maximilians University, Munich, Germany.
⁵ Comprehensive Heart Failure Centre, University Hospital Würzburg, Würzburg, Germany.
⁶ Collaborative Research Centre Cardioimmune Interfaces (SFB 1525), Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
⁷ Translational Radiopharmaceutical Sciences, Lausanne University, Lausanne, Switzerland; and.
⁸ Agora pôle de recherche sur le cancer, Lausanne, Switzerland.
⁹ Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; buck_a@ukw.de.

No abstract available